Ikona BIP Ikona Portal Pracownika Ikona poczty Facebook Twitter Instagram Youtube Linkedin RSS Ikona szukania PLEN

Miners donate blood plasma to help manufacture a medicine against COVID-19

The first Polish medicine against COVID-19 will be produced by Biomed in Lublin. 160 liters of plasma are required to make the first batch of the drug. To date, miners have donated 30 liters of this valuable resource.

- We are working on a medicine that will be created from blood plasma collected from individuals who have recovered from the coronavirus infection. There are a number of miners who have been infected with the virus and have recovered. They are now able to share an unusual “gift” that has developed in their bodies, namely the antibodies that are found in their blood plasma.  By donating their plasma, they can contribute very significantly to saving other people’s good health and even lives.  It is extremely important for patients, because this virus is going to stay with us forever - explains Piotr Fic, Management Board Member for Operations at Biomed Lublin SA.

Using the available technology, by processing the collected plasma, Biomed will be able to manufacture a medicine that will help in the future treatment of COVID-19 patients.

- Without the plasma collected from people who have recovered from COVID-19, the medicine will not be made. Only the generosity of donors will make its production possible. The attitude adopted by miners is extremely uplifting. By donating their plasma, not only will they be able to save human lives and health, but also they will contribute to the endeavors aimed at ensuring Poland’s independence from the supply of medicines from abroad. This patriotic attitude deserves great respect - adds Piotr Fic.

According to the manufacturer, if everything goes according to plan and clinical trials confirm the effectiveness of the medicine, it may appear on the market as early as next year. However, a lot will depend on how long the registration process with the Medicine Registration Authority will take.

- Blood plasma is a biological material, which is why we pay extreme attention to the safety of the people who work with it and the patients who use it. In the fractionation process, we rid the plasma of any unnecessary genetic material, deactivate any viruses and bacteria and then, from among the proteins found in the plasma, we select the right ones to obtain the purest product - explains Artur Bielawski, Production Director at Biomed, and adds: - Plasma antibodies are the main weapon in our fight against coronavirus. Only following the completion of a complex production process will we be able to manufacture the finished product in an ampule, which will then be administered to the patients. We have to be 100% sure that the medicine is safe both for patients and for the environment - emphasizes Artur Bielawski.

The plasma for the medicine to be manufactured by Biomed has been donated predominantly by miners from Jastrzębska Spółka Węglowa. This valuable resource will be provided to Biomed by the Regional Blood Donation and Treatment Center in Racibórz, which was the first such center in Poland to enter into cooperation aimed at obtaining plasma from individuals who have recovered from COVID-19 to enable the production of a medicine against this disease.

- We are extremely happy to have established cooperation both with Biomed and with Jastrzębska Spółka Węglowa and its miners. They are a strong and responsible group of people who are willing and ready to help. They have never let us down and this time they also swiftly responded to our call for help. I grew up in Silesia myself, my husband is a miner and I know that you can always count on miners. Once again, I would like to call on the residents of Silesia to donate plasma and also blood, which we need so badly - says Gizela Kowol, Director of the Regional Blood Donation and Treatment Center in Racibórz.

160 liters of plasma are required to manufacture the first batch of the preparation for the phase of clinical trials. This means that plasma must be collected from approx. 200 individuals who have recovered from COVID-19.

Other news

New longwalls in Pniówek and Knurów

Yesterday, longwall N-9 was commissioned at the Pniówek mine, providing reserves of high-quality coking coal of 308,000 tons. The longwall is 106 meters long and its strike is 658 meters. Its height is 4.2 meters. It was equipped with 69 powered support sections. The…

JSW increases coal and coke production in Q3

In Q3 2026, the Jastrzębska Spółka Węglowa Group produced 3.31 million tons of coal and 0.74 million tons of coke. Compared to the previous quarter, coal production increased by 2.7 percent and coke production by 10.6 percent.

Results of the 13th edition of the JSW OHS Competition announced. The winner is Marcin Kubicki

240 employees, nine months of competition and challenging questions on occupational health and safety. On 30 September, the 13th edition of the “Internet Competition of OHS Knowledge,” organized by Jastrzębska Spółka Węglowa SA, came to a close. The winner of this…

JSW Group’s financial results for H1 2026

The JSW Group ended the first half of 2026 with a net loss of PLN 1.04 billion, less than half the amount recorded in the corresponding period of last year. In Q2, the Group’s net loss totaled PLN 427.5 million, compared with a loss of PLN 615.9 million recorded in the…

JSW adopts the Remedy Program for 2026-2035

The Remedy Program is intended to ensure the JSW Group’s long-term improvement in profitability, financial liquidity and the alignment of its scale of operations with market and operational conditions. It includes both measures to stabilize the financial standing in the…

Internet broadcast of the results of the JSW Capital Group for the H1 of 2026 year

The Management Board of Jastrzębska Spółka Węglowa S.A. has the pleasure of inviting you to watch the Internet broadcast of the financial results of the JSW Group for the H1 of 2026 year which will take place on September 30, 2026 (Wednesday) at 10:00 (CET).

More news